6,302
Views
10
CrossRef citations to date
0
Altmetric
Report

Influence of the bispecific antibody IgG subclass on T cell redirection

, , ORCID Icon, , &
Pages 1012-1024 | Received 15 Mar 2019, Accepted 23 May 2019, Published online: 26 Jun 2019
 

ABSTRACT

T cell redirection mediated by bispecific antibodies (BsAbs) is a promising cancer therapy. Dual antigen binding is necessary for potent T cell redirection and is influenced by the structural characteristics of a BsAb, which are dependent on its IgG subclass. In this study, model BsAbs targeting CD19xCD3 were generated in variants of IgG1, IgG2, and IgG4 carrying Fc mutations that reduce FcγR interaction, and two chimeric IgG subclasses termed IgG1:2 and IgG4:2, in which the IgG1- or IgG4-F(ab)2 are grafted on an IgG2 Fc. Molecules containing an IgG2 or IgG4-F(ab)2 domain were confirmed to be the most structurally compact molecules. All BsAbs were shown to bind both of their target proteins (and corresponding cells) equally well. However, CD19xCD3 IgG2 did not bind both antigens simultaneously as measured by the absence of cellular clustering of T cells with target cells. This translated to a reduced potency of IgG2 BsAbs in T-cell redirection assays. The activity of IgG2 BsAbs was fully restored in the chimeric subclasses IgG4:2 and IgG1:2. This confirmed the major contribution of the F(ab)2 region to the BsAb’s functional activity and demonstrated that function of BsAbs can be modulated by engineering molecules combining different Fc and F(ab)2 domains.

Abbreviations: ADCC: Antibody-dependent cellular cytotoxicity; AlphaScreenTM: Amplified Luminescent Proximity Homogeneous Assay Screening; ANOVA: Analysis of variance; BiTE: bispecific T-cell engager; BSA: bovine serum albumin; BsAb: bispecific antibody; cFAE: controlled Fab-arm exchange; CDC: complement-dependent cellular cytotoxicity; CIEX: cation-exchange; CIR: chimeric immune receptor; DPBS: Dulbecco’s phosphate-buffered saline; EC50 value: effective concentration to reach half-maximum effect; EGFR: epidermal growth factor receptor; EI: expansion index (RAt=x/RAt=0); FACS: fluorescence-activated cell sorting; FVD: fixable viability dye; HI-HPLC: hydrophobic interaction HPLC; HI-FBS: heat-inactivated fetal bovine serum; HPLC: high-pressure liquid chromatography; IC50 value: effective concentration to reach half-maximum inhibition; IQ: Inhibition Quotient; IS: immunological synapse; MES: 2-(N-morpholino)ethanesulfonic acid; R-PE: recombinant phycoerythrin; RA: red area in μm2/well; RD: receptor density; RFP: red fluorescent protein; Rg: radius of gyration; RSV: respiratory syncytial virus; SAXS: small-angle x-ray scattering; scFv: single-chain variable fragment; SD: standard deviation; SPR: surface plasmon resonance; WT: wild-type

Acknowledgments

We acknowledge Nele Vloemans (Oncology Biology & Discovery Janssen Research and Development, Belgium) for the RFP-transduction of cell lines; Renouard Sanders (Janssen Diagnostics, Janssen Research and Development, Huntingdon Valley, PA, USA) for unimolar PE-labelling of molecules for receptor density experiments; Luc Gabriels (Discovery Sciences, Screening BE, Janssen Research and Development, Beerse, Belgium) for mycoplasma testing of cell lines, Anthony Armstrong (Biologics Research, Janssen Research and Development, Spring House, PA, USA) for coordinating structural SAXS measurements with the Illinois Institute of Technology. This work was supported by the Flemish Agency for Innovation and Entrepreneurship (IWT.145054 – ImmunoTherapy).

Disclosure of interest

Janssen Research and Development provided funding for the research. All authors are/were employees of Janssen Research and Development.

Supplemental material

Supplemental data for this article can be accessed on the publisher’s website.

Additional information

Funding

This work was supported by the Flemish Agency for Innovation and Entrepreneurship [IWT.145054 – ImmunoTherapy].